&lt;p&gt;A narrative review of psoriasis and multiple sclerosis: links and risks&lt;/p&gt;

Silfvast‐Kaiser, Annika; Homan, Katie B.; Mansouri, Bobbak

doi:10.2147/ptt.s186637

Cited by 23 publications

(33 citation statements)

References 85 publications

(112 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Psoriasis is an autoimmune inflammatory disorder that may affect the skin, associating epidermal proliferation, due to a dysregulation of the immune system; pro-inflammatory cytokines, including IL-12 and -23 and TNF-α, are produced, and the inflammatory milieu is developed and maintained with contribution from various cells, such as T-helper cells 1 and 17, keratinocytes, and dendritic cells alongside various immune cells [119][120][121][122].…”

Section: Psoriasismentioning

confidence: 99%

Cannabinoids in the Pathophysiology of Skin Inflammation

et al. 2020

View full text Add to dashboard Cite

Cannabinoids are increasingly-used substances in the treatment of chronic pain, some neuropsychiatric disorders and more recently, skin disorders with an inflammatory component. However, various studies cite conflicting results concerning the cellular mechanisms involved, while others suggest that cannabinoids may even exert pro-inflammatory behaviors. This paper aims to detail and clarify the complex workings of cannabinoids in the molecular setting of the main dermatological inflammatory diseases, and their interactions with other substances with emerging applications in the treatment of these conditions. Also, the potential role of cannabinoids as antitumoral drugs is explored in relation to the inflammatory component of skin cancer. In vivo and in vitro studies that employed either phyto-, endo-, or synthetic cannabinoids were considered in this paper. Cannabinoids are regarded with growing interest as eligible drugs in the treatment of skin inflammatory conditions, with potential anticancer effects, and the readiness in monitoring of effects and the facility of topical application may contribute to the growing support of the use of these substances. Despite the promising early results, further controlled human studies are required to establish the definitive role of these products in the pathophysiology of skin inflammation and their usefulness in the clinical setting.

show abstract

Section: Psoriasismentioning

confidence: 99%

Cannabinoids in the Pathophysiology of Skin Inflammation

et al. 2020

View full text Add to dashboard Cite

show abstract

“…While some small studies and case reports have suggested an increased risk, larger studies were unable to confirm this finding. 7 The role of TNF in demyelinating disorders is yet incompletely understood, and several cases developing multiple sclerosis and Guillain-Barr e in patients receiving TNF-blockers have been reported. 7 As psoriasis requires a long-term treatment, patients with a history of malignancy or developing cancer during systemic psoriasis treatment are a relatively frequent event.…”

Section: Introductionmentioning

confidence: 99%

“…7 The role of TNF in demyelinating disorders is yet incompletely understood, and several cases developing multiple sclerosis and Guillain-Barr e in patients receiving TNF-blockers have been reported. 7 As psoriasis requires a long-term treatment, patients with a history of malignancy or developing cancer during systemic psoriasis treatment are a relatively frequent event. Psoriasis patients carry an increased risk for different types of cancer and cancer mortality especially from liver, oesophageal and pancreatic cancer and lymphoma.…”

Section: Introductionmentioning

confidence: 99%

Practical recommendations for systemic treatment in psoriasis in case of coexisting inflammatory, neurologic, infectious or malignant disorders (BETA‐PSO: Belgian Evidence‐based Treatment Advice in Psoriasis; part 2)

Lambert

Segaert²,

Ghislain

et al. 2020

Acad Dermatol Venereol

View full text Add to dashboard Cite

Background Psoriasis patients carry an increased risk for associated comorbidities. Dermatologists have to be aware of the effects of systemic treatments not only on psoriasis but also on co‐occurring diseases. In case of other coexisting inflammatory diseases, the right psoriasis treatment may improve both disorders. For infectious and malignant disorders, some treatments have to be avoided as they may be harmful. Objective The primary objective of this project was to collect evidence for the creation of practice guidelines for systemic treatment of psoriasis (BETA‐PSO: Belgian Evidence‐based Treatment Advice in Psoriasis). Methods Evidence‐based recommendations were formulated using a quasi‐Delphi methodology after a systematic search of the literature and a consensus procedure involving eight psoriasis experts. Results Recommendations are given on the use of systemic treatment in psoriatic arthritis, inflammatory bowel disease, demyelinating disorders, hepatitis B and C, HIV and cancer. Conclusion This expert opinion is a practical guide for dermatologists when handling psoriasis patients with these specific conditions.

show abstract

“…Psoriasis is a chronic, immune-mediated, inflammatory disorder with an estimated prevalence of approximately 2% to 4% in Europe. 1 Moderate to severe psoriasis is frequently associated to several comorbidities, such as abdominal obesity, hypertension, diabetes mellitus, dyslipidemia, cardiovascular disorder, and chronic kidney disease. 2 Multiple sclerosis is the most common immune-mediated demyelinating disease of the central nervous system (CNS) affecting young adults with a strong female prevalence.…”

Section: Introductionmentioning

confidence: 99%

“…2 Multiple sclerosis is the most common immune-mediated demyelinating disease of the central nervous system (CNS) affecting young adults with a strong female prevalence. 1 Psoriasis and multiple sclerosis present similarities in genetic risk factors and immune system dysregulation. 1 The association between these two conditions has been suggested but, to date, it is not clearly elucidated since results of multiple studies are conflicting.…”

Section: Introductionmentioning

confidence: 99%

Combination treatment with secukinumab and dimethyl fumarate in a patient with psoriasis and recent diagnosis of multiple sclerosis

Tullio

Odorici

Lasagni

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

The therapeutic approach to patients with psoriasis and concomitant multiple sclerosis is challenging. We report the clinical case of a 44-year-old man affected by psoriasis and psoriatic arthritis treated with secukinumab for 2 years, who received also dimethyl fumarate because of a recent diagnosis of relapsing remitting multiple sclerosis. Moreover, a mini-review of the available literature regarding the use of secukinumab in patients with psoriasis or ankylosing spondylitis and coexisting central nervous system demyelinating diseases was performed. To the best of our knowledge, this is the first case of successfully combining secukinumab and dimethyl fumarate for the treatment of two different immune mediated inflammatory diseases with good response and safety outcomes. Our case emphasizes the potential efficacy of this combination therapy, which may represent an effective synergistic strategy to manage such challenging patients.

show abstract

<p>A narrative review of psoriasis and multiple sclerosis: links and risks</p>

Cited by 23 publications

References 85 publications

Cannabinoids in the Pathophysiology of Skin Inflammation

Cannabinoids in the Pathophysiology of Skin Inflammation

Practical recommendations for systemic treatment in psoriasis in case of coexisting inflammatory, neurologic, infectious or malignant disorders (BETA‐PSO: Belgian Evidence‐based Treatment Advice in Psoriasis; part 2)

Combination treatment with secukinumab and dimethyl fumarate in a patient with psoriasis and recent diagnosis of multiple sclerosis

Contact Info

Product

Resources

About